Orion Portfolio Solutions LLC Has $275,000 Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Orion Portfolio Solutions LLC decreased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 17.2% during the 3rd quarter, Holdings Channel reports. The firm owned 6,114 shares of the company’s stock after selling 1,274 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Protagonist Therapeutics were worth $275,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in PTGX. New York State Teachers Retirement System acquired a new stake in shares of Protagonist Therapeutics during the third quarter worth approximately $1,107,000. Seven Eight Capital LP grew its position in Protagonist Therapeutics by 426.9% during the 2nd quarter. Seven Eight Capital LP now owns 36,793 shares of the company’s stock worth $1,275,000 after acquiring an additional 29,810 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Protagonist Therapeutics by 9.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 204,299 shares of the company’s stock valued at $7,079,000 after purchasing an additional 17,065 shares in the last quarter. Swedbank AB acquired a new stake in Protagonist Therapeutics during the 3rd quarter valued at $2,250,000. Finally, Charles Schwab Investment Management Inc. raised its position in Protagonist Therapeutics by 7.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 565,503 shares of the company’s stock valued at $25,448,000 after purchasing an additional 39,850 shares during the last quarter. 98.63% of the stock is owned by institutional investors.

Analyst Ratings Changes

PTGX has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Protagonist Therapeutics in a report on Tuesday, December 10th. TD Cowen upgraded shares of Protagonist Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 25th. Truist Financial started coverage on shares of Protagonist Therapeutics in a research report on Monday, September 9th. They set a “buy” rating and a $60.00 target price on the stock. StockNews.com lowered shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Finally, The Goldman Sachs Group assumed coverage on Protagonist Therapeutics in a report on Friday, December 6th. They set a “neutral” rating and a $47.00 price objective on the stock. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $53.78.

Insiders Place Their Bets

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 78,520 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $46.96, for a total value of $3,687,299.20. Following the completion of the sale, the chief executive officer now owns 435,208 shares of the company’s stock, valued at approximately $20,437,367.68. This represents a 15.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Arturo Md Molina sold 1,906 shares of Protagonist Therapeutics stock in a transaction on Friday, November 15th. The stock was sold at an average price of $40.98, for a total transaction of $78,107.88. Following the transaction, the insider now directly owns 46,444 shares in the company, valued at approximately $1,903,275.12. This represents a 3.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 209,863 shares of company stock worth $9,689,847. Insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Stock Up 1.3 %

NASDAQ:PTGX opened at $39.54 on Friday. Protagonist Therapeutics, Inc. has a 12-month low of $20.71 and a 12-month high of $48.89. The stock’s fifty day simple moving average is $44.09 and its 200-day simple moving average is $40.80. The firm has a market capitalization of $2.36 billion, a P/E ratio of 14.86 and a beta of 2.18.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.